open access publication

Article, 2023

Fertility preservation in women with benign gynaecological conditions

HUMAN REPRODUCTION OPEN, Volume 2023, 2, 10.1093/hropen/hoad012

Contributors

Santulli, P. 0000-0002-4985-7326 (Corresponding author) [1] [2] [3] [4] [5] [6] Blockeel, C. [7] [8] [9] Bourdon, Mathilde [2] [3] [4] [5] [6] Coticchio, Giovanni 0000-0003-1635-9205 [10] Campbell, Alison [11] De Vos, Michel 0000-0001-5019-5924 [8] [9] Macklon, K. T. [12] [13] Pinborg, A. 0000-0002-8340-104X Garcia-Velasco, Juan A. 0000-0003-1005-8727 [14] [15]

Affiliations

  1. [1] CHU Cochin Batiment Port Royal, Serv Gynecol Obstetr II & Med Reprod, 123 Blvd Port Royal, Paris 14, France
  2. [NORA names: France; Europe, EU; OECD];
  3. [2] Univ Paris 05, Hop Univ Paris Ctr HUPC, AP HP, Paris, France
  4. [NORA names: France; Europe, EU; OECD];
  5. [3] Ctr Hosp Univ Cochin CHU, Dept Gynecol & Obstetricsand Reprod Med Prof Chapr, Paris, France
  6. [NORA names: France; Europe, EU; OECD];
  7. [4] Univ Paris 05, Inst Cochin, Dept Dev, Sorbonne Paris Cite, Paris, France
  8. [NORA names: France; Europe, EU; OECD];
  9. [5] Sorbonne Paris Cite, Fac Med, Paris, France
  10. [NORA names: France; Europe, EU; OECD];

Abstract

Although a wealth of data has been published regarding fertility preservation (FP) in women with malignant diseases who receive gonadotoxic treatment, the role of FP in non-malignant conditions has been studied to a much lesser extent. These include benign haematological, autoimmune, and genetic disorders, as well as a multitude of benign gynaecological conditions (BGCs) that may compromise ovarian reserve and/or reproductive potential due to pathogenic mechanisms or as a result of medical or surgical treatments. Alongside accumulating data that document the reproductive potential of cryopreserved oocytes and ovarian tissue, there is potential interest in FP for women with BGCs at risk of infertility; however, there are currently insufficient data about FP in women with BGCs to develop guidelines for clinical practice. The purpose of this article is to appraise the available evidence regarding FP for BGC and discuss potential strategies for FP based on estimated ovarian impairment and on short-term and long-term reproductive goals of patients. Cost-effectiveness considerations and patients' perspectives will also be discussed.

Keywords

adenomyosis, cryopreservation, endometriosis, female infertility, fertility preservation, oocyte quality, ovarian reserve, ovary, premature ovarian insufficiency

Data Provider: Clarivate